laudanosine

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
Laudanosine is a metabolite of the neuromuscular-blocking drugs atracurium and cisatracurium with potentially toxic systemic… (More)
Is this relevant?
1995
1995
To ascertain the effects of chronic renal failure on the pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (a stereoisomer… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • table 4
Is this relevant?
1991
1991
Several groups of investigators have reported that the plasma concentrations of laudanosine, a metabolite of atracurium, are high… (More)
Is this relevant?
1990
1990
The concentration of laudanosine in cerebrospinal fluid (CSF) was measured in four patients undergoing brain electrode placement… (More)
Is this relevant?
1989
1989
The pharmacokinetics of a bolus dose of atracurium 0.6 mg kg-1 and its metabolite laudanosine were studied in 11 elderly (mean… (More)
Is this relevant?
1987
1987
Twenty patients in the intensive care unit received an infusion of atracurium to permit mechanical ventilation. The duration of… (More)
  • table I
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1986
1986
Laudanosine, which is a degradation product of atracurium, is a convulsant drug in the rat. Laudanosine plasma concentrations… (More)
Is this relevant?
1985
1985
The authors hypothesized that laudanosine, a metabolite of atracurium and a central nervous system stimulant, might increase the… (More)
Is this relevant?
1985
1985
Patients with renal failure and undergoing a cadaver renal transplant were found to have plasma concentrations of laudanosine… (More)
  • figure 1
Is this relevant?
1984
1984
The authors determined the pharmacokinetics (including transfer into cerebrospinal fluid [CSF]) and the cardiovascular and… (More)
Is this relevant?